Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 5/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14863997 | 0.83 | ALDH1A1 (0.43) | KMT2AFAAHMMP2MMP9MMP14 | |
| SCHEMBL6191577 | 0.82 | KMT2A (0.49) | KMT2AFAAHMGLLMMP2MMP9 | |
| SCHEMBL10812056 | 0.79 | KMT2A (0.63) | KMT2AMGLLMMP2MMP9MMP8 | |
| SCHEMBL20342007 | 0.78 | KMT2A (0.56) | KMT2AACHESMN1; SMN2NPC1RAB9A | |
| SCHEMBL13944297 | 0.78 | KMT2A (0.54) | KMT2AMGLLMMP2MMP9MMP8 | |
| SCHEMBL13911210 | 0.78 | GAA (0.59) | KMT2AFAAHMGLLMMP2MMP9 | |
| SCHEMBL1690926 | 0.78 | KMT2A (0.54) | KMT2AMGLLMMP2MMP9MMP8 | |
| SCHEMBL2453184 | 0.78 | KMT2A (0.54) | KMT2AMGLLMMP2MMP9MMP8 | |
| SCHEMBL12412446 | 0.77 | PKM (0.49) | KMT2AMGLLMMP2MMP9MMP8 | |
| SCHEMBL25226904 | 0.76 | RAB9A (0.61) | KMT2AFAAHMGLLMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110165112-A1 | POLYMER CONJUGATES OF C-PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165112-A1 | POLYMER CONJUGATES OF C-PEPTIDES | IAPP, GCG, INSR | KMT2A 4468/4885FAAH 4304/4885MGLL 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.